Prime Therapeutics experts examine how GLP-1 discontinuation trends shape benefit strategies, patient outcomes and long-term affordability

cover image for Cell & Gene Pipeline Outlook: January 2026 Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-january-2026 Prime Therapeutics’ Cell & Gene...

Jessica Johnson, clinical consultant at Prime's Special Investigations Unit, shares how to identify fake GLP-1s

Live updates from AMCP Annual Meeting

Drug Approvals Monthly Update: March 2024 Traditional New drugs 3/04/2024 clobetasol propionate 0.05% The FDA approved the first clobetasol propionate ophthalmic formulations. The 0.05% suspension...

cover image Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-june-2026 Prime Therapeutics’ Cell & Gene Pipeline Outlook is an industry report that...

High discontinuation rates highlight the importance of patient support programs to maximize the value of GLP-1 therapies

Cover for 2023 January Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_jan?fr=sODMzODc3NDc1ODQ About...

Cover for 2023 April Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_apr?fr=xKAE9_zU1NQ About Prime...

Cover for 2023 July Quarterly Pipeline a view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_jul?fr=sMjFiMTc3NDc1ODQ About...